New treatments for asthma

European Journal of Internal Medicine

Volumn 11, Issue 1, 2000, Pages 9-20

  Barnes, Peter J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Anti inflammatory; Asthma; Bronchodilator; Corticosteroid

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CYTOKINE; EOTAXIN; FORMOTEROL; FUROSEMIDE; IMMUNOGLOBULIN E; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 4; INTERLEUKIN 5; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SALMETEROL; TIOTROPIUM BROMIDE;

ASTHMA; DRUG EFFICACY; DRUG SAFETY; GENE THERAPY; HUMAN; IMMUNOMODULATION; PATIENT COMPLIANCE; REVIEW; TREATMENT INDICATION;

EID: 0033974473     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0953-6205(99)00071-0     Document Type: Review

References (121)

1. Jones T.R., Charette L., Garcia M.L., Kaczorowski G.J. Interaction of iberiotoxin with β-adrenoceptor agonists and sodium nitroprusside on guinea pig trachea. J Appl Physiol. 74:1993;1879-1884.
2. Miura M., Belvisi M.G., Stretton C.D., Yacoub M.H., Barnes P.J. Role of potassium channels in bronchodilator responses in human airways. Am Rev Respir Dis. 146:1992;132-136.
3. Ca channels in airway smooth muscle by cAMP-dependent and -independent mechanisms. J Clin Invest. 93:1994;371-379.
4. Drazen J.M., Israel E., Boushey H.A., et al. Comparison of regularly scheduled with as needed use of albuterol in mild asthma. New Engl J Med. 335:1996;841-847.
5. Chapman K.R., Ringdal N., Backer V., Palmqvist M., Saarelainen S., Briggs M. Salmeterol and fluticasone propionate (50/250 mg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers. Can Respir J. 6:1999;45-51.
6. Palmer J.B.D., Cuss F.M.C., Barnes P.J. VIP and PHM and their role in nonadrenergic inhibitory responses in isolated human airways. J Appl Physiol. 61:1986;1322-1328.
7. Barnes P.J., Dixon C.M.S. The effect of inhaled vasoactive intestinal peptide on bronchial hyperreactivity in man. Am Rev Respir Dis. 130:1984;162-166.
8. O'Donnel M., Garippa R.J., Rinaldi N., et al. Ro25-1553: a novel long-acting vasoactive intestinal peptide agonist. Part 1: in vitro and in vivo bronchodilator studies. J Pharmacol Exp Ther. 270:1994;1282-1288.
9. Coleman R.A., Smith W.L., Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev. 46:1994;205-229.
10. 2. Lancet. 344:1995;436-438.
11. Waldeck B., Widmark E. Comparison of the effects of forskolin and isoprenaline on tracheal, cardiac and skeletal muscles from guinea-pig. Eur J Pharmacol. 112:1985;349-353.
12. Angus R.M., Mecallaum M.J.A., Hulks G., Thomson N.C. Bronchodilator, cardiovascular and cyclic guanylyl monophosphate response to high dose infused atrial natriuretic peptide in asthma. Am Rev Respir Dis. 147:1993;1122-1125.
13. Angus R.M., Millar E.A., Chalmers G.W., Thomson N.C. Effect of inhaled atrial natriuretic peptide and a neutral endopeptidase inhibitor on histamine-induced bronchoconstriction. Am J Respir Crit Care Med. 151:1995;2003-2005.
14. Hamad A.M., Range S., Holland E., Knox A.J. Regulation of cGMP by soluble and particulate guanylyl cyclases in cultured human airway smooth muscle. Am J Physiol. 273:1997;L807-L813.
15. Fluge T., Fabel H., Wagner T.O., Schneider B., Forssmann W.G. Urodilatin (ularitide, INN): a potent bronchodilator in asthmatic subjects. Eur J Clin Invest. 25:1995;728-736.
16. Belvisi M.G., Stretton C.D., Barnes P.J. Nitric oxide is the endogenous neurotransmitter of bronchodilator nerves in human airways. Eur J Pharmacol. 210:1992;221-222.
17. Barnes P.J., Belvisi M.G., Mak J.C.W., Haddad E., O'Connor B. Tiotropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease. Life Sci. 56:1995;853-859.
18. Disse B., Speck G.A., Rominger K.L., Witek T.J., Hammer R. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci. 64:1999;457-464.
19. Garcia M., Galvez A., Garcia-Calvo M., King V.F., Vazquez J., Kaczorowski G.J. Use of toxins to study potassium channels. J Bioenerg Biomembr. 23:1991;615-646.
20. Black J.L., Barnes P.J. Potassium channels and airway function: new therapeutic approaches. Thorax. 45:1990;213-218.
21. Buckle D.R. Prospects for potassium channel activators in the treatment of airways obstruction. Pulm Pharmacol. 6:1993;161-169.
22. Black J.L., Armour C.L., Johnson P.R.A., Alouan L.A., Barnes P.J. The action of a potassium channel activator BRL38227 (lemakalim) on human airway smooth muscle. Am Rev Respir Dis. 142:1990;1384-1389.
23. Kidney J.C., Fuller R.W., Worsdell Y., Lavender E.A., Chung K.F., Barnes P.J. Effect of an oral potassium channel activator BRL38227 on airway function and responsiveness in asthmatic patients: comparison with oral salbutamol. Thorax. 48:1993;130-134.
24. + channel inhibitor iberiotoxin with β-adrenoceptor agonists on isolated guinea pig trachea. Am Rev Respir Dis. 145:1992;A203.
25. + channels in bovine tracheal smooth muscle cells in culture. Br J Pharmacol. 116:1995;1656-1660.
26. Fox A.J., Barnes P.J., Venkatesan P., Belvisi M.G. Activation of large conductance potassium channels inhibits the afferent and efferent function of airway sensory nerves. J Clin Invest. 99:1997;513-519.
27. Barnes P.J., Chung K.F., Page C.P. Inflammatory mediators of asthma: an update. Pharmacol Rev. 50:1998;515-596.
28. Drazen J.M., Israel E., O'Byrne P.M. Treatment of asthma with drugs modifying the leukotriene pathway. New Engl J Med. 340:1999;197-206.
29. Clark J.M., Abraham W.M., Fishman C.E., et al. Tryptase inhibitors block allergen-induced airway and inflammatory responses in allergic sheep. Am J Respir Crit Care Med. 152:1995;2076-2083.
30. Krishna M.T., Chauhan A.J., Little L., et al. Effect of inhaled APC 366 on allergen-induced bronchoconstriction and airway hyperresponsivness to histamine in atopic subjects. Am J Respir Crit Care Med. 157:1998;A456.
31. Chung K.F., Barnes P.J. Cytokines in asthma. Thorax. 54:1999;825-857.
32. Egan R.W., Umland S.P., Cuss F.M., Chapman R.W. Biology of interleukin-5 and its relevance to allergic disease. Allergy. 51:1996;71-81.
33. Mauser P.J., Pitman A.M., Fernandez X., et al. Effects of an antibody to interleukin-5 in a monkey model of asthma. Am J Respir Crit Care Med. 152:1995;467-472.
34. Leckie M.J., ten Brincke A., Lordan J., et al. SB 240563, a humanized anti-IL-5 monoclonal antibody. Initial single dose safety and activity in patients with asthma. Am J Respir Crit Care Med. 159:1999;A624.
35. Hogan S.P., Matthaei K.I., Young J.M., Koskinen A., Young I.G., Foster P.S. A novel T-cell-regulated mechanism modulating allergen-induced airways hyperreactivity in BALB/c mice independently of IL-4 and IL-5. J Immunol. 161:1998;1501-1509.
36. Gavett S.H., O'Hearn D.J., Karp C.L., Patel E.A., Schofield B.H., Finkelman F.D., Wills-Karp M. Interleukin-4 receptor blockade prevents airway responses induced by antigen challenge in mice. Am J Physiol. 272:1997;L253-61.
37. Borish L.C., Nelson H.S., Lanz M., Clausen L.B., Martin D.W., Garrison L. Phase I/II study of interleukin-4 receptor (IL-4R) in moderate asthma. J Allergy Clin Immunol. 101:1998;S8.
38. Foster P.S. STAT6: an intracellular target for the inhibition of allergic disease. Clin Exp Allergy. 29:1999;12-16.
39. Losman J.A., Chen X.P., Hilton D., Rothman P. Cutting edge: SOCS-1 is a potent inhibitor of IL-4 signal transduction. J Immunol. 162:1999;3770-3774.
40. Wills-Karp M., Luyimbazi J., Xu X., Schofield B., Neben T.Y., Karp C.L., Donaldson D.D. Interleukin-13: central mediator of allergic asthma. Science. 282:1998;2258-2261.
41. Li L., Xia Y., Nguyen A., Lai Y.H., Feng L., Mosmann T.R., Lo D. Effects of Th2 cytokines on chemokine expression in the lung: IL-13 potently induces eotaxin expression by airway epithelial cells. J Immunol. 162:1999;2477-2487.
42. Chomarat P., Banchereau J. Interleukin-4 and interleukin-13: their similarities and discrepancies. Int Rev Immunol. 17:1998;1-52.
43. Feldman M., Taylor P., Paleolog E., Brennan F.M., Maini R.N. Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn's disease: analysis of the mechanism of action predicts utility in other diseases. Transplant Proc. 30:1998;4126-4127.
44. Luster A.D. Chemokines - chemotactic cytokines that mediate inflammation. New Engl J Med. 338:1998;436-445.
45. Heath H., Qin S., Rao P., et al. Chemokine receptor usage by human eosinophils. The importance of CCR3 demonstrated using an antagonistic monoclonal antibody. J Clin Invest. 99:1997;178-184.
46. Elsner J., Petering H., Hochstetter R., Kimmig D., Wells T.N., Kapp A., Proudfoot A.E. The CC chemokine antagonist Met-RANTES inhibits eosinophil effector functions through the chemokine receptors CCR1 and CCR3. Eur J Immunol. 27:1997;2892-2898.
47. Barnes P.J., Lim S. Inhibitory cytokines in asthma. Mol Med Today. 4:1998;452-458.
48. Selig W., Tocker J. Effect of interleukin-1 receptor antagonist on antigen-induced pulmonary responses in guinea-pigs. Eur J Pharmacol. 213:1992;331-336.
49. Rosenwasser L.J. Biologic activities of IL-1 and its role in human disease. J Allergy Clin Immunol. 102:1998;344-350.
50. Pretolani M., Goldman M. IL-10: a potential therapy for allergic inflammation? Immunol Today. 18:1997;277-280.
51. Borish L., Aarons A., Rumbyrt J., Cvietusa P., Negri J., Wenzel S. Interleukin-10 regulation in normal subjects and patients with asthma. J Allergy Clin Immunol. 97:1996;1288-1296.
52. John M., Lim S., Seybold J., Robichaud A., O'Connor B., Barnes P.J., Chung K.F. Inhaled corticosteroids increase IL-10 but reduce MIP-1a, GM-CSF and IFN-g release from alveolar macrophages in asthma. Am J Respir Crit Care Med. 157:1998;256-262.
53. Zuany-Amorim C., Haile S., Leduc D., Dumarey C., Huerre M., Vargaftig B.B., Pretolani M. Interleukin-10 inhibits antigen-induced cellular recruitment into the airways of sensitized mice. J Clin Invest. 95:1995;2644-2651.
54. van Deventer S.J., Elson C.O., Fedorak R.N. Multiple doses of intravenous interleukin-10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology. 113:1997;383-389.
55. Seldon P.M., Barnes P.J., Giembycz M.A. Interleukin-10 does not mediate the inhibitory effect of PDE4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumor necrosis factor-a generation from human peripheral blood monocytes. Cell Biochem Biophys. 28:1998;179-201.
56. Lack G., Bradley K.L., Hamelmann E., et al. Nebulized IFN-gamma inhibits the development of secondary allergic responses in mice. J Immunol. 157:1996;1432-1439.
57. Boguniewicz M., Martin R.J., Martin D., Gibson U., Celniker A. The effects of nebulized recombinant interferon-γ in asthmatic airways. J Allergy Clin Immunol. 95:1995;133-135.
58. Benjaponpitak S., Oro A., Maguire P., Marinkovich V., DeKruyff R.H., Umetsu D.T. The kinetics of change in cytokine production by CD4 T-cells during conventional allergen immunotherapy. J Allergy Clin Immunol. 103:1999;468-475.
59. + T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol. 97:1996;1356-1365.
60. Gately M.K., Renzetti L.M., Magram J., Stern A.S., Adorini L., Gubler U., Presky D.H. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol. 16:1998;495-521.
61. Gavett S.H., O'Hearn D.J., Li X., Huang S.K., Finkelman F.D., Wills-Karp M. Interleukin-12 inhibits antigen-induced airway hyperresponsiveness, inflammation and Th2 cytokine expression in mice. J Exp Med. 182:1995;1527-1536.
62. Leonard J.P., Sherman M.L., Fisher G.L., et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-production. Blood. 90:1997;2541-2548.
63. Kim T.S., DeKruyff R.H., Rupper R., Maecker H.T., Levy S., Umetsu D.T. An ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production. J Immunol. 158:1997;4137-4144.
64. Vayssiere B.M., Dupont S., Choquart A., et al. Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit anti-inflammatory activity in vivo. Mol Endocrinol. 11:1997;1245-1255.
65. Torphy T.J. Phosphodiesterase isoenzymes. Am J Respir Crit Care Med. 157:1998;351-370.
66. Chan S.C., Hanifin J.M. Differential inhibitor effects on phosphodiesterase isoforms in atopic and normal leukocytes. J Lab Clin Med. 121:1993;44-51.
67. Harbison P.L., MacLeod D., Hawksworth R., et al. The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CD840) on allergen-induced responses in asthmatic subjects. Eur Respir J. 10:1997;1008-1014.
68. Muller T., Engels P., Fozard J. Subtypes of the type 4 cAMP phosphodiesterase: structure, regulation and selective inhibition. Trends Pharmacol Sci. 17:1996;294-298.
69. 2-adrenoreceptor desensitization. J Biol Chem. 273:1998;20575-20588.
70. Barnes P.J., Karin M. Nuclear factor-kB: a pivotal transcription factor in chronic inflammatory diseases. New Engl J Med. 336:1997;1066-1071.
71. Barnes P.J., Adcock I.M. Transcription factors and asthma. Eur Respir J. 12:1998;221-234.
72. Pahl H.L., Krauss B., Schultze-Osthoff K., et al. The immunosuppressive fungal metabolite gliotoxin specifically inhibits transcription factor NF-kB. J Exp Med. 183:1996;1829-1840.
73. Karin M. Mitogen-activated protein kinase cascades as regulators of stress responses. Ann New York Acad Sci. 851:1998;139-146.
74. Schafer P.H., Wadsworth S.A., Wang L., Siekierka J.J. p38Alpha mitogen-activated protein kinase is activated by CD28-mediated signaling and is required for IL-4 production by human CD4+CD45RO+ T-cells and Th2 effector cells. J Immunol. 162:1999;7110-7119.
75. Kankaanranta H., Giembycz M.A., Barnes P.J., Lindsay D.A. SB203580, an inhibitor of p38 mitogen-activated protein kinase, enhances constitutive apoptosis of cytokine-deprived human eosinophils. J Pharmacol Exp Ther. 290:1999;621-628.
76. Costello P.S., Turner M., Walters A.E., Cunningham C.N., Bauer P.H., Downward J., Tybulewicz V.L. Critical role for the tyrosine kinase syk in signalling through the high-affinity IgE receptor of mast cells. Oncogene. 13:1996;2595-2605.
77. Yousefi S., Hoessli D.C., Blaser K., Mills G.B., Simon H.U. Requirement of lyn and syk tyrosine kinases for the prevention of apoptosis by cytokines in human eosinophils. J Exp Med. 183:1996;1407-1414.
78. Amoui M., Draber P., Draberova L. Src family-selective tyrosine kinase inhibitor, PP1, inhibits both Fc epsilonRI- and Thy-1-mediated activation of rat basophilic leukemia cells. Eur J Immunol. 27:1997;1881-1886.
79. Alexander A.G., Barnes N.C., Kay A.B. Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. Lancet. 339:1992;324-328.
80. Nizankowska E., Soja J., Pinis G., et al. Treatment of steroid-dependent bronchial asthma with cyclosporin. Eur Respir J. 8:1995;1091-1099.
81. Morley J. Cyclosporin A in asthma therapy: a pharmacological rationale. J Autoimmun. 5:(Suppl A):1992;265-269.
82. Bieber T. Topical tacrolimus (FK 506): a new milestone in the management of atopic dermatitis [editorial; comment]. J Allergy Clin Immunol. 102:1998;555-557.
83. Thompson A.G., Starzl T.C. New immunosuppressive drugs: mechanistic insights and potential therapeutic advances. Immunol Rev. 136:1993;71-98.
84. Pilewski J.M., Albelda S.M. Cell adhesion molecules in asthma: homing activation and airway remodelling. Am J Respir Cell Mol Biol. 12:1995;1-3.
85. Weg V.B., Williams T.J., Lobb R.R., Noorshargh S. A monoclonal antibody recognizing very late activation antigen-4 inhibits eosinophil accumulation in vivo. J Exp Med. 177:1993;561-566.
86. Sun J., Elwood W., Haczku A., Barnes P.J., Hellewell P.G., Chung K.F. Contribution of intracellular adhesion molecule-1 in allergen-induced airway hyperesponsiveness and inflammation in sensitised Brown-Norway rats. Int Arch Allergy Immunol. 104:1994;291-295.
87. Yuan Q., Strauch K.L., Lobb R.R., Hemler M.E. Intracellular single-chain antibody inhibits integrin VLA-4 maturation and function. Biochem J. 318:1996;591-596.
88. 1 that inhibit allergic airway responses. J Med Chem. 42:1999;920-934.
89. Abraham W.M., Ahmed A., Sabater J.R., et al. Selectin blockade prevents antigen-induced late bronchial responses and airway hyperresponsiveness in allergic sheep. Am J Respir Crit Care Med. 159:1999;1205-1214.
90. Kim M.K., Brandley B.K., Anderson M.B., Bochner B.S. Antagonism of selectin-dependent adhesion of human eosinophils and neutrophils by glycomimetics and oligosaccharide compounds. Am J Respir Cell Mol Biol. 19:1998;836-841.
91. Heinke S., Szucs G., Norris A., Droogmans G., Nilius B. Inhibition of volume-activated chloride currents in endothelial cells by chromones. Br J Pharmacol. 115:1995;1393-1398.
92. 2+ and phorbol ester effect on the mast cell phosphoprotein induced by cromolyn [in process citation]. Eur J Pharmacol. 371:1999;241-249.
93. Bianco S., Pieroni M.G., Refini R.M., Robuschi M., Vaghi A., Sestini P. Inhaled loop diuretics as potential new anti-asthmatic drugs. Eur Respir J. 6:1993;130-134.
94. Yates D.H., O'Connor B.J., Yilmaz G., Aikman S., Chen-Worsdell M., Barnes P.J., Chung K.F. Effect of acute and chronic inhaled furosemide on bronchial hyperresponsiveness in mild asthma. Am J Respir Crit Care Med. 152:1995;892-896.
95. Haczku A., Takeda K., Redai I., et al. Anti-CD86 (B7.2) treatment abolishes allergic airway hyperresponsiveness in mice [in process citation]. Am J Respir Crit Care Med. 159:1999;1638-1643.
96. Van Oosterhout A.J., Hofstra C.L., Shields R., Chan B., van Ark I., Jardieu P.M., Nijkamp F.P. Murine CTLA4-IgG treatment inhibits airway eosinophilia and hyperresponsiveness and attenuates IgE upregulation in a murine model of allergic asthma. Am J Respir Cell Mol Biol. 17:1997;386-392.
97. van Neerven R.J., Van de Pol M.M., van der Zee J.S., Stiekema F.E., De Boer M., Kapsenberg M.L. Requirement of CD28-CD86 costimulation for allergen-specific T-cell proliferation and cytokine expression [see comments]. Clin Exp Allergy. 28:1998;808-816.
98. Kon O.M., Sihra B.S., Compton C.H., Leonard T.B., Kay A.B., Barnes N.C. Randomised dose-ranging placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma. Lancet. 352:1998;1109-1113.
99. Schwarze J., Cieslewicz G., Joetham A., Ikemura T., Hamelmann E., Gelfand E.W. CD8 T-cells are essential in the development of respiratory syncytial virus-induced lung eosinophilia and airway hyperresponsiveness. J Immunol. 162:1999;4207-4211.
100. Zhang D.H., Cohn L., Ray P., Bottomly K., Ray A. Transcription factor GATA-3 is differentially expressed in murine Th1 and Th2 cells and controls Th2-specific expression of the interleukin-5 gene. J Biol Chem. 272:1997;21597-21603.
101. Caramori G., Lim S., Ciaccia A., Fabbri L.M., Barnes P.J., Adcock I.M. GATA transcription factor expression in T-cells, monocytes and bronchial biopsies of normal and asthmatic subjects. Am J Respir Crit Care Med. 157:1999;A908.
102. Murphy E., Shibuya K., Hosken N., et al. Reversibility of T helper 1 and 2 populations is lost after long-term stimulation. J Exp Med. 183:1996;901-913.
103. Corne J., Djukanovic R., Thomas L., et al. The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics. J Clin Invest. 99:1997;879-887.
104. Fahy J.V., Fleming H.E., Wong H.H., et al. The effect of an anti-IgE monoclonal antibody on the early and late phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med. 155:1997;1828-1834.
105. Coyle A.J., Wagner K., Bertrand C., Tsuyuki S., Bews J., Heusser C. Central role of immunoglobulin (Ig) E in the induction of lung eosinophil infiltration and T helper 2 cell cytokine production: inhibition by a non-anaphylactoid anti-IgE antibody. J Exp Med. 183:1996;1303-1310.
106. Milgrom H., Fick R.B. Jr., Su J.Q., Reimann J., Bush R.K., Watrous M.L., Metzger W.J. Treatment of allergic asthma with monoclonal anti-IgE antibody. New Engl J Med. 341:1999;1966-1973.
107. Barnes P.J. Anti-IgE therapy: promising in severe asthma. New Engl J Med. 341:1999;2006-2008.
108. Creticos P.S., Reed C.E., Norman P.S., et al. Ragweed immunotherapy in adult asthma. New Engl J Med. 334:1996;501-506.
109. Barnes P.J. Immunotherapy for asthma: is it worth it? New Engl J Med. 334:1996;531-532.
110. Hsu C.H., Chua K.Y., Tao M.H., Lai Y.L., Wu H.D., Huang S.K., Hsieh K.H. Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization [see comments]. Nat Med. 2:1996;540-544.
111. Yssel H., Fasler S., Lamb J., de Vries J.E. Induction of non-responsiveness in human allergen specific type 2 helper cells. Curr Opin Immunol. 6:1994;847-852.
112. Norman P.S., Ohman J.L. Jr., Long A.A., et al. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med. 154:1996;1623-1628.
113. Haselden B.M., Barry Kay A., Larche M. Immunoglobulin E-independent major histocompatibility complex-restricted T-cell peptide epitope-induced late asthmatic reactions. J Exp Med. 189:1999;1885-1894.
114. Shirakawa T., Enomoto T., Shimazu S., Hopkin J.M. The inverse association between tuberculin responses and atopic disorder. Science. 275:1997;77-79.
115. Strannegard I.L., Larsson L.O., Wennergren G., Strannegard O. Prevalence of allergy in children in relation to prior BCG vaccination and infection with atypical mycobacteria. Allergy. 53:1998;249-254.
116. Herz U., Gerhold K., Gruber C., Braun A., Wahn U., Renz H., Paul K. BCG infection suppresses allergic sensitization and development of increased airway reactivity in an animal model. J Allergy Clin Immunol. 102:1998;867-874.
117. Wang C.C., Rook G.A. Inhibition of an established allergic response to ovalbumin in BALB/c mice by killed Mycobacterium vaccae. Immunology. 93:1998;307-313.
118. Wheeler M.A., Smith S.D., Garcia Cardena G., Nathan C.F., Weiss R.M., Sessa W.C. Bacterial infection induces nitric oxide synthase in human neutrophils. J Clin Invest. 99:1997;110-116.
119. Sur S., Wild J.S., Choudhury B.K., Sur N., Alam R., Klinman D.M. Long-term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides [in process citation]. J Immunol. 162:1999;6284-6293.
120. Xing Z., Ohkawara Y., Jordana M., Grahern F.L., Gauldie J. Transfer of granulocyte-macrophage colony-stimulating factor gene to rat induces eosinophilia, monocytosis and fibrotic lesions. J Clin Invest. 97:1996;1102-1110.
121. Nyce J.W., Metzger W.J. DNA antisense therapy for asthma in an animal model. Nature. 385:1997;721-725.